Pharmacy Times

FEBRUARY 14, 2024

Despite the growth in vaccine and antibody development for combatting RSV, lower income countries may not reap the benefits.

Vaccines 149

Vaccines 149

STAT

FEBRUARY 14, 2024

Public health messages have told us for decades that if you smoke, you should quit. And if you don’t smoke, don’t start. But a new study suggests smoking may be even worse than we thought. The study , published Wednesday in Nature, underscores the importance of never lighting up that first cigarette, based on its conclusion that smoking has much longer harmful effects on immune responses than previously understood.

Immunization 144

Immunization 144

Pharmacy Times

FEBRUARY 14, 2024

Continued doses of denosumab reduced the incidence of diabetes by more than 1000 patients compared to an initial dose alone.

145

145

STAT

FEBRUARY 14, 2024

The Federal Trade Commission is launching a probe into the extent to which group purchasing organizations and wholesalers may contribute to ongoing shortages of key medicines at hospitals and other facilities across the country. The agency will explore how these companies — which are responsible for brokering and distributing countless medicines — might misuse their market power to influence pricing and availability.

Nursing Homes 140

Nursing Homes Hospitals Chemotherapy 140

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Pharmacy Times

FEBRUARY 14, 2024

Researchers will continue to research how lantibiotic’s antimicrobial effects can be harnessed for good.

139

139

STAT

FEBRUARY 14, 2024

Last week, the Washington Post published an op-ed by former CDC Director Tom Frieden titled, “It’s the world’s leading killer. Make it the focus of the next breakthrough.” Frieden writes, “Hypertension, the ‘silent killer,’ is the deadliest but most neglected and widespread pandemic of our time, killing more than 10 million people a year worldwide.

140

140

STAT

FEBRUARY 14, 2024

If you have high blood pressure, it’s increasingly likely that your doctor or your insurer will offer you a blood pressure cuff or an educational app to help you get it under control. While potentially impactful, these tools may not be reaching marginalized people who don’t regularly have access to good health care — and who may benefit the most from the tools.

Insurance 140

Insurance 140

Pharmacy Times

FEBRUARY 14, 2024

The approval of irinotecan liposome offers an improved first-line treatment option for individuals diagnosed with metastatic pancreatic adenocarcinoma.

FDA 131

FDA 131

STAT

FEBRUARY 14, 2024

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was  followed by  eight additional adalimumab biosimilar launches. These nine  FDA-approved  products offer lower-cost alternatives to the  world’s bestselling drug, Humira , used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders.

FDA 139

FDA 139

pharmaphorum

FEBRUARY 14, 2024

Discover how artificial intelligence (AI) is revolutionising the drug development process and transforming the way FDA-approved drugs are produced, ensuring compliance and optimising the supply chain. Learn more about the future of AI in pharmaceuticals.

FDA 129

FDA 129

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

FEBRUARY 14, 2024

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals. The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

138

138

Pharmacy Times

FEBRUARY 14, 2024

Repotrectinib led to a durable anti-tumor response in patients with NTRK-positive locally advanced or metastatic solid tumors.

FDA 122

FDA 122

STAT

FEBRUARY 14, 2024

A leaked version of a proposed agreement between India and the European Free Trade Association is causing alarm among civil society and patient advocacy groups over concerns the deal would delay access to affordable generic versions of newer, lifesavings medicines for several years. The language in a draft agreement, which is expected to be concluded by April, suggests changes would have to be made to India’s patent and regulatory laws.

135

135

Fierce Pharma

FEBRUARY 14, 2024

FDA unleashes multiple warning letters targeting insanitary manufacturing and online sales of unapproved Mounjaro, Ozempic fkansteiner Wed, 02/14/2024 - 05:10

FDA 122

FDA 122

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Drug Store News

FEBRUARY 14, 2024

Instacart revealed that it would lay off about 250 employees, or approximately 7% of the company, as it restructures, according to a letter to shareholders.

116

116

Fierce Pharma

FEBRUARY 14, 2024

Over the last month, for those watching HBO’s macabre “True Detective Night Country”—a TV series set in a harsh, sunless winter in a fictional Alaskan town—a continual theme is frostbite. | The FDA has approved the first medicine for severe frostbite. The U.S. regulator has signed off on Johnson & Johnson’s Aurlumyn (iloprost), an injected treatment to reduce the risk of amputation of the fingers or toes.

FDA 122

FDA 122

STAT

FEBRUARY 14, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hello! And it’s Meghana again. Today, we discuss how Biogen’s missed the mark with Leqembi, but how it’s also not exactly a surprise. We see a new startup emerge that aims to compete with Vertex Pharmaceuticals, and learn of Phase 1 results for Replicate’s srRNA rabies vaccine.

Vaccines 115

Vaccines 115

Fierce Pharma

FEBRUARY 14, 2024

With another quarter exceeding analysts’ expectations, Blueprint Medicines has raised its peak sales estimate for rare disease drug Ayvakit to $2 billion. | With another quarter exceeding analysts’ expectations, Blueprint Medicines has raised its peak sales estimate for rare disease drug Ayvakit to $2 billion.

118

118

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

The Checkup by Singlecare

FEBRUARY 14, 2024

While the primary goal of diabetes medications is to regulate blood sugar levels, some have the added benefit of helping with weight loss. One such medication is Mounjaro (tirzepatide), a GLP-1 receptor agonist manufactured by the pharmaceutical company Eli Lilly. It stimulates insulin production, decreases appetite, and slows digestion. In addition to improved glucose control, it commonly helps patients reduce their food intake.

Dosage 115

Dosage Labelling FDA Pharmaceutical Companies 115

Fierce Pharma

FEBRUARY 14, 2024

Biogen’s business has been in decline thanks to fierce multiple sclerosis competition and a botched Alzheimer’s drug launch. To make matters worse, the U.S. | Biogen’s business has been in decline thanks to fierce multiple sclerosis competition and a botched Alzheimer’s drug launch. To make matters worse, the U.S. Department of Justice is looking into the company’s foreign operations.

117

117

Fierce Healthcare

FEBRUARY 14, 2024

Would-be policy reformers on both the left and right always seem to want major overhauls of the American healthcare system. | As clinicians, it's critical for us to be open and accountable for adopting technologies and processes that can help us better serve our patients while meeting the needs of the business.

114

114

Drug Topics

FEBRUARY 14, 2024

Participants of a recent study who experienced more daily cognitive symptoms had a greater likelihood of reporting moderate interference with functioning, less likelihood of full-time employment, and greater severity of depressive symptoms.

112

112

STAT

FEBRUARY 14, 2024

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.

112

112

pharmaphorum

FEBRUARY 14, 2024

Eicos Sciences' Aurlumyn has become the first FDA-approved drug treatment to prevent amputations in cases of severe frostbite

FDA 110

FDA 110

Fierce Pharma

FEBRUARY 14, 2024

Even as Australia’s CSL continues to grow, the company’s ambitions for its kidney disease and iron deficiency outfit Vifor Pharma—now known as CSL Vifor—have become more muted. | Even as Australia’s CSL continues to grow, the company’s ambitions for its kidney disease and iron deficiency outfit Vifor Pharma—now known as CSL Vifor—have become more muted.

109

109

pharmaphorum

FEBRUARY 14, 2024

Ipsen has won FDA approval for first-line use of its pancreatic cancer therapy Onivyde, saying it is now part of a potential new “standard-of-care” for patients

FDA 105

FDA 105

Fierce Pharma

FEBRUARY 14, 2024

Sage Therapeutics and Biogen may not have the broad label that they had hoped for with Zurzuvae, but the two companies are still touting the med’s initial launch performance in postpartum depressio | Sage Therapeutics and Biogen may not have the broad label that they had hoped for with Zurzuvae, but the two companies are touting the med’s initial launch performance in postpartum depression.

Labelling 102

Labelling FDA 102

Drug Topics

FEBRUARY 14, 2024

Long-Term Care (LTC) pharmacies are playing a critical role in delivering care primarily for our aging population. Yet LTC pharmacies face many challenges, including rising costs, space constraints, labor availability and many others.

98

98

European Pharmaceutical Review

FEBRUARY 14, 2024

Gilead Sciences has agreed to acquire CymaBay Therapeutics for a total equity value of $4.3 billion. Gilead confirmed that CymaBay’s lead product candidate seladelpar has a best-in-disease profile for second-line primary biliary cholangitis (PBC). This is based on data from the Phase III RESPONSE trial. The company shared that seladelpar is an oral, selective peroxisomeproliferator-activated receptor delta (PPARδ) agonist.

97

97

Drug Topics

FEBRUARY 14, 2024

Young women with breast cancer have a less favorable prognosis compared with older women. However, data on recent trends and period and cohort effects among young women are not well known.

98

98

European Pharmaceutical Review

FEBRUARY 14, 2024

The development of drug products containing live anaerobic bacterial strains as the active pharmaceutical ingredient and where potency and shelf-life is typically associated with viable cell quantification, poses unique challenges when compared to both small and large molecule development therapeutics. It is the uniqueness of the strain and perceived inter-cellular variations (sub-populations) resulting from high viable cell densities during growth (fermentation) and the subsequent harvest and d

Dosage 97

Dosage Packaging Compounding Labelling 97

Fierce Healthcare

FEBRUARY 14, 2024

Elevance Health's $2.5 billion acquisition of Blue Cross and Blue Shield of Louisiana is on pause yet again amid concerns about the impact on competition. | Elevance Health's $2.5 billion acquisition of Blue Cross and Blue Shield of Louisiana is on pause yet again amid concerns about the impact on competition.

95

95

European Pharmaceutical Review

FEBRUARY 14, 2024

A report by Allied Market Research predicts that the global pharmaceutical suspension market will reach $83.8 billion by 2032. Having valued $55.5 billion in 2022, the research expected that the market will reach a CAGR of 4.2 percent between 2023 and 2032. Factors driving the global pharmaceutical suspension market One of the main factors anticipated to propel the growth of the pharmaceutical suspension market is the availability of generic pharmaceutical suspensions, the research asserted.

95

95